01873 VIVA BIOTECH
- 0.580
- +0.020+3.57%
VIVA BIOTECH News
Changes in Hong Kong stocks | CRO concept stocks continue to rebound, the downstream demand side needs to improve, and domestic CXO companies still have a competitive advantage
CRO concept stocks continued to rebound. As of press release, Viva Biotech (01873) rose 8.93% to HK$0.61; Kingsley Biotech (01548) rose 8.35% to HK$11.94; Kanglong Chemical (03759) rose 5.91% to HK$10.04; and Pharmaceutical Biotech (02269) rose 5.79% to HK$14.26.
維亞生物：2023年度報告
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 34% Share Price Slump
To the annoyance of some shareholders, Viva Biotech Holdings (HKG:1873) shares are down a considerable 34% in the last month, which continues a horrid run for the company. The recent drop completes
Viva Biotech (01873) announced annual results, losses attributable to shareholders of 116 million yuan narrowed by 78.03% year-on-year
Viva Biotech (01873) announced its annual results for the year ended December 31, 2023, with group revenue of RMB 21...
VIVA BIOTECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
Viva Biotech (01873.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Glonghui, March 18, 丨 ViaBio (01873.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).
VIVA BIOTECH: DATE OF BOARD MEETING
Changes in Hong Kong stocks | CRO concept stocks pick up in early trading, many CRO companies issued clarifying announcements, government work reports first mention “innovative drugs”
The Zhitong Finance App learned that CRO concept stocks picked up in early trading. As of press release, Viva Biotech (01873) rose 5.05% to HK$0.52; Pharmaceutical Kangde (02359) rose 4.11% to HK$46.85; Tiger Pharmaceuticals (03347) rose 3.66% to HK$25.5; Kanglong Chemical (03759) rose 3.89% to HK$46.75; Pharmaceutical Biotech (02269) rose 3.16% to HK$17.62. According to the news, on March 6, the US Senate Homeland Security Committee held a hearing on the proposal. The US Senate version of “Biosecurity”
Trending Industry Today: PHARMARON Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
March 4th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up, 1 constituents down and PHARMARON leadi
Viva Biotech (01873.HK) appoints Wang Hui as non-executive director
Gelonghui, January 18, 丨 Via Biotech (01873.HK) announced that Mr. Wang Hui has been appointed as a non-executive director with effect from January 18, 2024.
Changes in Hong Kong stocks | Viva Biotech (01873) fell nearly 8%, leading the CRO concept to fall, the obstacle of high overseas interest rates is expected to eliminate the still weak domestic demand for innovative drugs
CRO concept stocks declined collectively. As of press release, Viva Biotech (01873) fell 7.95% to HK$0.81; Fangda Holdings (01521) fell 6.82% to HK$2.05; Kanglong Chemical (03759) fell 6.74% to HK$13; and Zhaoyan Pharmaceutical (06127) fell 6.57% to HK$1.66.
Strong trend in CRO sector, Pharmaco-Biotech (02269) rises 10%, institutions say sector financing is gradually picking up
Jinwu Financial News | The CRO sector is trending strongly, with Pharmaceutical Biotech (02269) rising 10% to lead the sector. Additionally, Pharmaceuticals (02268) rose 7.87%, Viva Biotech (01873) rose 5.43%, Kanglong Chemical (03759) rose 4.25%, Tiger Pharmaceuticals (03347) rose 3.92%, and Kingsley Biotech (01548) rose 3.84%. Zheshang Securities said that in the CXO industry, financing is gradually picking up and is poised to improve. Overseas clinical demand is still strong and may be picking up before clinical trials. 2023Q1-Q3 Domestic investment and financing has returned to the 2017Q
Viva Biotech (01873.HK): Complete redemption of US$280 million 1.00% of the secured convertible bonds due in 2025
Glonghui, January 3, 丨 Via Biotech (01873.HK) announced that according to the terms and conditions of the convertible bonds, bondholders holding convertible bonds with a total principal amount of US$136.6 million (about 48.8% of the total principal amount of the convertible bonds originally issued) have exercised their option to require the issuer to redeem all of their convertible bonds on December 30, 2023, in the amount of 103.08% of the principal amount together with accrued but unpaid interest up to that date (not including that date). As of the announcement date, all convertible bonds have been redeemed and no convertible bonds remain unpaid. The company has traded jointly with Hong Kong
Changes in Hong Kong stocks | CRO concept stocks collectively strengthened, US inflation exceeded expectations, and domestic investment and financing increased sharply from month to month in November
CRO concept stocks strengthened collectively. As of press release, Viva Biotech (01873) rose 8.16% to HK$1.06; Zhaoyan Pharmaceutical (06127) rose 6.94% to HK$12.94; and Tiger Pharmaceuticals (03347) rose 6.83% to HK$35.2.
VIVA Biotech Sells 2.3% Stake in Viva Biotech (Shanghai)
VIVA Biotech Holdings (HKG:1873) has sold a 2.3% stake in Viva Biotech (Shanghai) in Raed Capital Holdings 2 for $15 million. Following completion, the biotechnology company's equity stake in Viva Bio
Via Biotech (01873.HK): Wang Hui has been nominated as a non-executive director
Gelonghui announced on December 22|Via Biotech (01873.HK) announced that Mr. Wang Hui has been nominated as a non-executive director. The appointment is subject to approval by the company's shareholders at the upcoming special general meeting of shareholders of the company.
ViaBio (01873.HK) proposes to adopt the ViaShanghai Phase I Equity Incentive Plan and the ViaShanghai Phase II Equity Incentive Plan
Glonghui, December 22|Viabiotech (01873.HK) announced that the company proposes to adopt the ViaShanghai Phase I Equity Incentive Plan and the ViaShanghai Phase II Equity Incentive Plan, which will enable ViaShanghai to incentivize its employees and directors.
VIVA Biotech Disposes of Minority Stake in Subsidiary for $15 Million
Raed Capital Holdings 2 will acquire about 2.3% of Viva Biotech (Shanghai) from its parent VIVA Biotech Holdings (HKG:1873) for a consideration of $15 million. The stake is worth $1.5 million in the d
ViaBio (01873.HK) plans to sell approximately 2.33% of Viavia Shanghai's shares for $15 million
Gelonghui, December 15, ViaBiotech (01873.HK) announced that on December 15, 2023, the company (together with several subsidiaries), Mr. Mao Chen, and the grantor Raed Capital Holdings 2 Ltd entered into an equity transfer agreement. According to this, the transferee will acquire $1,536,611 of ViaBiotech's registered capital in Shanghai at a cost of $15 million (accounting for about 2.33% of its registered capital). Via Shanghai is an indirect non-wholly owned subsidiary of the Company. As of the date of this announcement, the Group held 75.79 of Viavia Shanghai's share capital
Analysis
Price Target
No Data
